OBJECTIVES: To investigate the incidence, characteristics, and prognostic impact of prior extrapancreatic malignancies on patients with pancreatic cancer (PDAC). METHODS: Records from 1733 patients who underwent surgery for PDAC were analyzed for the occurrence of prior extrapancreatic malignancies. Patients' records showing extrapancreatic malignancies were then analyzed for tumor type, epidemiological data, risk factors, PDAC tumor stage, and long-term survival. RESULTS: A total of 239 patients with PDAC (13.8%) had a history of 271 extrapancreatic tumors; 26 patients had a history of two pancreatic cancers, and 3 patients had 3 extrapancreatic cancers. The most common extrapancreatic tumors were breast cancer (56 patients) and prostate cancer (41 patients), followed by colorectal, reno/urothelial, and gynecologic tumors (39, 32, and 23 patients, respectively). No significant difference in overall survival was found between patients with PDAC with or without extrapancreatic malignancies. CONCLUSIONS: Pancreatic cancer is associated with extrapancreatic malignancies in a remarkable number of patients. A history of extrapancreatic malignancies does not influence prognosis and should not be an obstacle to a curative therapeutic approach. Surveillance of patients with extrapancreatic malignancies, especially breast, prostate, and colorectal cancer, could allow for earlier PDAC diagnosis and therefore improve prognosis of these patients.
OBJECTIVES: To investigate the incidence, characteristics, and prognostic impact of prior extrapancreatic malignancies on patients with pancreatic cancer (PDAC). METHODS: Records from 1733 patients who underwent surgery for PDAC were analyzed for the occurrence of prior extrapancreatic malignancies. Patients' records showing extrapancreatic malignancies were then analyzed for tumor type, epidemiological data, risk factors, PDAC tumor stage, and long-term survival. RESULTS: A total of 239 patients with PDAC (13.8%) had a history of 271 extrapancreatic tumors; 26 patients had a history of two pancreatic cancers, and 3 patients had 3 extrapancreatic cancers. The most common extrapancreatic tumors were breast cancer (56 patients) and prostate cancer (41 patients), followed by colorectal, reno/urothelial, and gynecologic tumors (39, 32, and 23 patients, respectively). No significant difference in overall survival was found between patients with PDAC with or without extrapancreatic malignancies. CONCLUSIONS:Pancreatic cancer is associated with extrapancreatic malignancies in a remarkable number of patients. A history of extrapancreatic malignancies does not influence prognosis and should not be an obstacle to a curative therapeutic approach. Surveillance of patients with extrapancreatic malignancies, especially breast, prostate, and colorectal cancer, could allow for earlier PDAC diagnosis and therefore improve prognosis of these patients.
Authors: Jung Hyun Jo; In Rae Cho; Jang Han Jung; Hee Seung Lee; Moon Jae Chung; Seungmin Bang; Seung Woo Park; Jae Bock Chung; Si Young Song; Jeong Youp Park Journal: PLoS One Date: 2017-06-26 Impact factor: 3.240
Authors: Sarah Schott; Rongxi Yang; Sarah Stöcker; Federico Canzian; Nathalia Giese; Peter Bugert; Frank Bergmann; Oliver Strobel; Thilo Hackert; Christof Sohn; Barbara Burwinkel Journal: Oncotarget Date: 2017-06-27
Authors: Martin Lovecek; Marketa Janatova; Pavel Skalicky; Tomas Zemanek; Roman Havlik; Jiri Ehrmann; Ondrej Strouhal; Petra Zemankova; Klara Lhotova; Marianna Borecka; Jana Soukupova; Hana Svebisova; Pavel Soucek; Viktor Hlavac; Zdenek Kleibl; Cestmir Neoral; Bohuslav Melichar; Beatrice Mohelnikova-Duchonova Journal: Cancer Manag Res Date: 2019-01-10 Impact factor: 3.989